Sugi Predict

Sugi Predict / Compounds / SCHEMBL722872

SCHEMBL722872

SCHEMBL722872

[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.92
▸ CYP3A4 P08684 1/20 0.92
▸ ESR1 P03372 4/20 0.63
▸ ESR2 Q92731 4/20 0.63
▸ KDM4E B2RXH2 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.37
▸ DRD1 P21728 2/20 0.35
▸ TSHR P16473 4/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ CA9 Q16790 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ CA12 O43570 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ CA3 P07451 1/20 0.33
▸ CA4 P22748 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1344 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL3710821 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL1747083 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL3931585 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL4718125 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL236600 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL5968399 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL224846 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL201704 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL22558063 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110156657-B Synthesis method of 4-aminoindole 兰州大学 2022-04-12 — — CN claimed
US-12595284-B2 Amatoxin antibody-drug conjugates and uses thereof HEIDELBERG PHARMA RESEARCH GMBH (DE) 2026-04-07 — — US disclosed
US-20260078148-A1 AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2026-03-19 — — US disclosed
US-20250176428-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2025-05-29 — — US disclosed
US-20240158365-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF AMAZENTIS SA (CH) 2024-05-16 — — US disclosed
US-20240158364-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF AMAZENTIS SA (CH) 2024-05-16 — — US disclosed
US-20240158363-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF AMAZENTIS SA (CH) 2024-05-16 — — US disclosed
US-20240139149-A1 THERAPEUTIC USES OF UROLITHIN DERIVATIVES VANDRIA SA (CH) 2024-05-02 — — US disclosed
CN-117695280-A Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors 福马治疗股份有限公司 2024-03-15 — — CN disclosed
WO-2024025953-A2 THERAPEUTIC USES OF UROLITHIN DERIVATIVES VANDRIA SA (CH) 2024-02-01 — — WO disclosed
EP-1778665-A1 PROCESS FOR THE PREPARATION OF 11-[(Z)-3-(DIMETHYLAMINO)PROPYLIDENE]-6,11-DIHYDRO-DIBENZ[B,E]OXEPIN-2-YL]ACETIC ACID Urquima S.A. (ES) 2007-05-02 — — EP disclosed
WO-2006010459-A1 PROCESS FOR THE PREPARATION OF 11-[(Z)-3-(DIMETHYLAMINO)PROPYLIDENE]-6,11-DIHYDRO-DIBENZ[B,E]OXEPIN-2-YL]-ACETIC ACID URQUIMA S.A. (ES) 2006-02-02 — — WO disclosed
US-6642256-B2 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders WARNER-LAMBERT COMPANY LLC 2003-11-04 — — US disclosed
EP-1345935-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS Warner-Lambert Company LLC (US) 2003-09-24 — — EP disclosed
WO-2003027105-A1 SUBSTITUTED 3-PYRIDYL THIOPHENES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 — — WO disclosed
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists KORNBERG BRIAN EDWARD (US) 2003-01-23 — — US disclosed
WO-2002050070-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2002-06-27 — — WO disclosed
US-5637593-A MIGRAINE; HYPOTENSIVE AGENTS SMITHKLINE BEECHAM PLC (GB) 1997-06-10 — — US disclosed
EP-0674619-A1 TRYPTAMINE ANALOGUES AS 5-HT 1?-LIKE AGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-10-04 — — EP disclosed
WO-1994014770-A1 TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158364-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF NLN, UQCRC2, TUFM TDP1 361/4885CYP3A4 4292/4885ESR1 4838/4885
US-20250176428-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, ODC1 TDP1 2820/4885CYP3A4 247/4885ESR1 71/4885
US-20240158363-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF NLN, UQCRC2, TUFM TDP1 361/4885CYP3A4 4292/4885ESR1 4838/4885
US-12595284-B2 Amatoxin antibody-drug conjugates and uses thereof HLA-DRB1, CD2, CD74 TDP1 4640/4885CYP3A4 4415/4885ESR1 4166/4885
US-20240158365-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF NLN, UQCRC2, TUFM TDP1 361/4885CYP3A4 4292/4885ESR1 4838/4885
US-20260078148-A1 AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF CD2, CD74, CD99 TDP1 3844/4885CYP3A4 3837/4885ESR1 274/4885
US-20240139149-A1 THERAPEUTIC USES OF UROLITHIN DERIVATIVES TNNT2, TNNI3, TNNC1 TDP1 787/4885CYP3A4 4839/4885ESR1 4880/4885
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists GRIN1, OPRD1, OPRM1 TDP1 2019/4885CYP3A4 2743/4885ESR1 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.